Amygdala-targeted neurofeedback for dissociative symptoms in PTSD: Converging evidence from three independent studies

Dissociative symptoms occur in 14-30% of PTSD cases and present significant treatment challenges. These symptoms may respond to amygdala-targeted neural regulation training.

Secondary analysis of patients with clinically significant dissociative symptoms (CAPS-5 Q29/Q30 >1) from three independent studies: Study 1 - comparison of amygdala neurofeedback + treatment-as-usual (n=14) vs. treatment-as-usual alone (n=7); Study 2 - single-arm neurofeedback study (n=14); Study 3 - comparison of amygdala neurofeedback (n=5) vs. control (n=2).

Large significant within-group improvements in both primary neurofeedback studies (Fine: d=1.82, p<0.001; Fruchter: d=0.85, p=0.007) contrasted with small non-significant effects in control groups. Mixed-effects analysis across all studies showed significant time effects (F=19.8, p<0.001) but non-significant Group × Time interactions. Specificity analysis revealed negligible correlations between dissociation improvements and other PTSD symptom changes (all r<0.17), indicating dissociation-specific rather than general therapeutic effects.

Convergent evidence from independent studies supports preliminary efficacy of amygdala-targeted neurofeedback for dissociative symptoms. Larger controlled trials with standardized protocols are warranted.